Screener
Acadia Pharmaceuticals ACAD Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's restricted cash?
- Acadia Pharmaceuticals (ACAD) reported restricted cash of $7.85M in Q2 2026.
- How has Acadia Pharmaceuticals's restricted cash changed year-over-year?
- Acadia Pharmaceuticals's restricted cash decreased by 17.2% year-over-year, from $9.47M to $7.85M.
- What is the long-term trend for Acadia Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's restricted cash has grown at a 6.3% compound annual growth rate (CAGR), from $5.77M to $7.85M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Acadia Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude